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BJNhem20-OCIAD1-CRISPR-20 line heterozygous knockout for
OCIAD1 was generated by targeting exon3 of OCIAD1 using CRISPR-. This is an open access article underCas9 mediated knockout strategy (Fig. 1A). The method is based on an
earlier report (Peters et al., Stembook 2013). BJNhem20 cells were co-
transfected with pCas9D10A-GFP and OCIAD1 sgRNA expression con-
structs targeting two sites on exon3 for double nickase activity.
Cas9D10A-GFP expressing cells were sorted and plated clonally on
mTESR containing Matrigel-coated dishes. Forty individual colonies
were picked and expanded for screening. Genomic DNA was isolated
and screened by high ﬁdelity PCR ampliﬁcation followed by sequencing
of exon3 of OCIAD1 at the targeted region. Seven heterozygous knock-
outs were obtained and one of them is BJNhem20-OCIAD1-CRISPR-20,
which was characterized further.
OCIAD1 depletion was validated by immunostaining and Western
blot analysis for OCIAD1 levels, in three biological replicates.
Expression of pluripotent stem cell markers OCT4, SSEA3/4, and
TRA1-81 has been shown by immunostaining. Differentiation of these
hESC lines to all the three germ layers was demonstrated by immuno-
staining for markers such as AFP (endoderm), Brachyury (mesoderm)
and β-III tubulin (ectoderm). Karyotype was also checked in these
cells and found to be normal.
Materials and methods
Cell culture
hESC line-BJNhem20 was derived from the discarded Grade III
embryos and tested for its pluripotency (Inamdar et al., 2009). This
cell line has been cultured continuously for over 200 passages without
acquiring karyotypic abnormality (Venu et al., 2010). The cell line was
included in the analysis of genetic stability in the International Stem
Cell Initiative project (ISCI2, 2011). Cultures of BJNhem20 and the trans-
genic line BJNhem20-OCIAD1-CRISPR-20 were maintained on mouse
embryonic ﬁbroblast feeder layers in hESC medium composed ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Expression and karyotype analysis of BJNhem20-OCIAD1-CRISPR-20 hESC line. (A) Strategy for targeting OCIAD1 exon3 by CRISPR-CAS9. (B) Chromatograms showing sequence
analysis to conﬁrm heterozygous mutation in the targeted region of OCIAD1. (C) Western blot analysis showing decreased OCIAD1 levels in BJNhem20-OCIAD1-CRISPR-20. Graph
represents standard error mean after analysis of four biological replicates using single factor ANOVA (P-value 1.12241E-06). (D) Karyotype analysis of BJNhem20-OCIAD1-CRISPR-20.
(E) Analysis of transcript levels of pluripotency marker genes Oct4, Nanog, TDGF and Sox2 by reverse transcription and polymerase chain reaction (RT-PCR) ampliﬁcation. GAPDH was
used to normalize transcript levels. (F) Immunostaining analysis of BJNhem20-OCIAD1-CRISPR-20 for depletion of OCIAD1 and for pluripotency markers Oct4, SSEA4 and TRA1-81 as
indicated, compared to parental hESCline BJNhem20. (G) Differentiation analysis of BJNhem20-OCIAD1-CRIPSR-20: Embryoid bodies stained to show differentiation to all the three
germ layers by immunostaining for AFP, Brachyury and βIII-Tubulin marking the endoderm, mesoderm and ectoderm respectively.
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ogies Cat no. 10829-018) supplemented with 20% KnockOut Serum re-
placement (KOSR-Life Technologies Cat no. 10828-028), 1% GlutaMAX
(Life Technologies Cat no. 35050-061), 1% non-essential amino acids
(MEM-NEAA-Life Technologies Cat no. 11140-050), 0.1% β-
mercaptoethanol (Life Technologies Cat no. 21985-023) and 8 ng/ml
human recombinant basic ﬁbroblast growth factor (human bFGF-
Sigma Aldrich Pvt. Ltd. Cat no. F-0291).These cells were routinely pas-
saged by mechanical cutting of undifferentiated colonies.
Electroporation of hESCs to generate BJNhem20-OCIAD1-CRISPR-20 cell
line
For electroporation, BJNhem20 cells were grown onMatrigel-coated
(BectonDickinson Cat. no. 354277) dishes inmTESRmedium (StemCellTechnologies Cat. no. 05850), until the culturewas 80% conﬂuent. To aid
survival of single cells post transfection the cultures were pre-treated
with ROCK inhibitor (10 μM Y-27632, Sigma Aldrich) for 3 h prior to
electroporation. The cells were trypsinized using 1× TrypLE (Life
Technologies Cat. no. 12605010) at 37 °C for 4 min. The cells were
pelleted by centrifugation at 1000 rpm for 2 min, washed with phos-
phate buffered saline and enumerated. 1million cells were resuspended
in 400 μl cold OptiMEM medium and mixed with plasmids pCAS9-
D10A-GFP (Addgene ID 44720) 5 μg, OCIAD1 CRISPR Left and Right
Exon3 targeting sgRNA expression constructs (Custom generated by
Genocopoeia) 2.5 μg each. Electroporation was performed in a 0.4 cm
Biorad electroporation cuvette at 250 mV, 500 μF for 10 milliseconds.
Immediately after electroporation 0.5 ml of cold mTESR1 medium was
added and the cells were transferred to a 15 ml centrifugation tube
and spun down at 1000 rpm for 2 min. The cells were resuspended in
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mTESR and fresh mTESR1 (1:1), 8 ng/ml bFGF, supplemented with
ROCK inhibitor (10 μMY-27632) and seeded onMatrigel-coated dishes.
16 h after electroporation the medium was replaced with mTESR1
medium without ROCK inhibitor.
Sorting of hESCs to generate BJNhem20-OCIAD1-CRISPR-20 cell line
GFP expression was monitored 48 h post transfection and after 72 h
cells were harvested as mentioned above for sorting GFP+ population.
The cells were resuspended in cold OptiMEM, passed through a 40 μm
pore size cell strainer and then sorted for GFP expression using BD
FACS ARIA II cell sorter. Sorted cells were collected in 15 ml centrifuge
tubes containing 5 ml of OptiMEM with Antibiotic-Antimycotic (Life
technologies Cat no. 15240-062). Post-sort the cells were incubated at
4 °C for 10 min, pelleted by centrifugation at 1000 rpm for 2 min and
resuspended in 2 ml of post-FACS recovery medium. 200 GFP positive
cells were seeded in 35mmMatrigel-coated dish in post-FACS recovery
medium with 10 μM ROCK inhibitor and 1× Antibiotic–Antimycotic.
Mediumwas replaced with fresh post-FACS recoverymedium (without
ROCK inhibitor) every 24 h.
Screening of BJNhem20OCIAD1-CRISPR and Cas9D10A transfected cultures
to generate BJNhem20-OCIAD1-CRISPR-20 cell line
Four days after FACS sorting, undifferentiated hESC colonies were
clearly visible and cultures were switched to regular mTESR medium.
Colonies were picked on day 8 and seeded individually on Matrigel-
coated wells of 24 well plate for clonal expansion. After passaging to
obtain duplicates, a single well of each clone was harvested and
screened for in-del mutations as described before (Peters et al.,
Stembook 2013). Brieﬂy, genomic DNA was isolated and PCR ampliﬁed
using high-ﬁdelity DNA polymerase (KAPA HiFi) and primers spanning
OCIAD1 exon3 (OCIAD1 Intron2F: 5′gggtgcctcttgttaatgtttaggc3′;
OCIAD1 Intron3R: 5′cagacagacctgttttcaactcca 3′), followed by PCR
Cleanup (Machery Nagel Kit), sequencing (Sanger's Sequencing).
Embryoid body differentiation
Differentiation of embryoid bodies was carried out as described
before (Inamdar et al., 2009). Brieﬂy, colonies grown onMEFswereme-
chanically cut and pieces cultured in human embryoid bodymedia (10%
FBS-Hyclone-SH30070 with β-mercaptoethanol and GlutaMAX in
DMEM) on low attachment plates. These hESC aggregates were allowed
to grow in suspension for 3 days after which the colonies formed
embryoid body-like structures and were transferred to tissue culture
dishes pre-treated with 0.1% gelatin and allowed to attach and differen-
tiate spontaneously till the time for harvest for immunostaining
analyses.
Immunostaining
hESC and hEBs were ﬁxed in 2% paraformaldehyde (in PBS), perme-
abilized with Triton-X 100 (0.1% for cells and 0.3% for EBs) and then
blocked with 4% FBS for 1 h at RT (Room Temperature). Post blocking,cells were incubatedwith the appropriate primary antibodies overnight
at 4 °C, washed with PBS at RT and incubated with secondary antibody
conjugated to either Alexa Fluor 488 or 568 for 1 h at RT (Dilution 1:400
Invitrogen).The cells were washed and stained using DAPI (1:500 inM1
buffer Invitrogen) to visualize nuclei. The images were acquired using
an epiﬂuorescence microscope (IX-81(Olympus)) ﬁtted with a cooled
CCD camera (CoolSnap, Roper Scientiﬁc). Primary antibodies used were
against OCIAD1 (AbcamAb91574), Oct4 (BD Biosciences BD611203),
TRA1-81 andSSEA4 (kindgift fromPeterAndrews, University of Shefﬁeld,
UK), Brachyury (Santa Cruz Biotech Cat no.SC-17743), β-III tubulin
(Santacruz SC-51670), AFP (Sigma Chemical Pvt. Ltd. Cat no. A8452).
RNA isolation, cDNA synthesis and PCR:
Total RNA was extracted from cells using TRIzol reagent (Life Tech-
nologies Cat no. 15596-026) following the manufacturer's instructions.
2 μg of DNase treated RNA was converted to cDNA by performing re-
verse transcription using Superscript II (Life Technologies Cat no.
18064-014). Primer sequences used for cDNA ampliﬁcation (5′–3′)
were as follows:rimer name Sequence
ct4_F gaaggtattcagccaaacgac
ct4_R gttacagaaccacactcgga
anog_F tgcaaatgtcttctgctgagat
anog_R gttcaggatgttggagagttc
pdh_F gtccatgccatcactgcca
pdh_R ttactccttggagccatg
gf_F tccttctacggacggaactg
gf_R agaaatgcctgaggaaagcatdVeriﬁcation of karyotype
Standard G banding of metaphase spreads was performed and
analyzed using CytoVision software. For each sample, at least 50
metaphases were counted and 10 were analyzed.
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